Do anticoagulants improve survival in patients presenting with venous thromboembolism?
Article first published online: 27 NOV 2003
Journal of Internal Medicine
Volume 254, Issue 6, pages 527–539, December 2003
How to Cite
Kelly, J. and Hunt, B. J. (2003), Do anticoagulants improve survival in patients presenting with venous thromboembolism?. Journal of Internal Medicine, 254: 527–539. doi: 10.1111/j.1365-2796.2003.01206.x
- Issue published online: 27 NOV 2003
- Article first published online: 27 NOV 2003
- Received 24 March 2003; revision received 5 May 2003; accepted 6 May 2003.
- deep vein thrombosis;
- pulmonary embolism;
- venous thromboembolism
Anticoagulants have been available since around 1940 and have become the standard of treatment for venous thromboembolism (VTE) for over four decades. However, as with other treatments which became established before the evidence-based era, there is a paucity of evidence from randomized controlled trials validating their effectiveness in preventing the most feared complication of VTE, recurrent fatal pulmonary embolism (PE). Only two such trials have been performed, the results of which conflict. The bulk of data supporting their use are derived from three sources. First, studies of thromboprophylaxis, and comparisons of shorter and longer courses of anticoagulants in high-risk patients with established VTE have clearly demonstrated their effectiveness in primary and late secondary prevention. Given that heparin has an immediate onset of action, anticoagulants should therefore also be effective in early secondary prevention, the proposed mechanism of action in the acute treatment of VTE. Secondly, studies of inadequately treated patients have consistently shown higher recurrence rates than in those adequately treated. Finally, comparisons of outcomes in untreated and treated historical series, and of untreated historical series to treated series in the modern era have shown substantially lower rates of fatal PE in anticoagulated patients. Because these differences are so marked, harmonize with our current understanding of the mechanism of action of anticoagulants and are supported by other evidence, it is much more likely that they at least partly reflect the effectiveness of anticoagulants as opposed to being explicable purely in terms of accumulated biases and a changing distribution of disease severity.